ASCO News: Avelumab (Bavencio,EMD Serono)-Cetuximab (Erbitux, Lilly) Combo Meets Primary Endpoint in Phase 2 cSCC Trial
The combination of avelumab (Bavencio,Pfizer) and cetuximab (Erbitux, Lilly) improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC), according to a Phase 2 clinical trial led by the Alliance for Clinical Trials in Oncology.